Stephen Stone, MD

Professor, Dermatology, Department of Internal Medicine, Director of Clinical Research
Dermatology

    About me

    Gender

    Male

    Education & training

    Positions
    Director of Clinical Research
    Board Certifications
    Dermatology
    Medical School
    New York University, New York, NY - MD - 1967
    Undergraduate Degree
    Tufts University, Medford, Massachusettes - BA - 1963
    Residency
    Lincoln Hospital, Albert Einstein College of Medicine, Bronx, NY - 1968
    Fellowship
    Mayo Graduate School of Medicine, Rochester, MN - 1974

    Research

    Research Interests
    Phase II and III Pharmaceutical Studies: Acne, Cutaneous Lupus, Psoriasis, Melanoma

    Publications

    Stone, SP:Carabao rash. (letter) Arch Derm., 102:564, 1979.
     
    Stone, SP, Muller, SA, and Gleich, GJ:IgE Levels in atopic dermatitis.  Arch Derm., 108:806, 1973.
     
    Stone SP. Bullous pemphigoid (letter) Arch Dermatol. 1974 Nov;110(5):812
     
    Stone SP. Delayed blanch in alopecia mucinosa. (letter) Arch Dermatol. 1975 Jan;111(1):132.
     
    Stone, SP, and Schroeter, AL:Bullous pemphigoid and as­sociated ­malignant neoplasms. Arch Derm., 111:994, 1975.
     
    Stone, SP:Urticaria, Journal of Family Practice, 2:6, 455, December 1975.
     
    Stone, SP:Cutaneous clues to cancer, American Family Physician, 12:4, 83, October 1975.
     
    Stone, SP, Gleich, GJ, and Muller, SA:Atopic dermatitis and IgE: relationship between changes in IgE levels and severity of dise­ase.Arch Derm., 112:1254, 1976.
     
    Stone, SP:Scabies.American Family Physician, 14:152, May 1977.
     
    Stone, SP, and Goodwin, RM:Dapsone induced jaundice, Arch Derm., 114:6, 47, June 1978.
     
    Stone, SP:Electrodessication and fulguration of lesions of the skin, Journal of Family Practice, 8:1, 171 - 174, January 1979.
     
    Stone, SP:Basal cell nevus syndrome and adenocarcinoma of the colon: response to intravenous 5-fluorouracil. Inter­nation­al Journal of Dermatology, 18:5, 398 - 401. June 1979.
     
    Stone, SP:"Rosacea" in Conn, H:Current Therapy:  1979, W. B. Saunders (Philadelphia) 1979.
     
    Stone, SP:Long Term Effects of Tetracycline (amenorrhea).Journal of the American Academy of Dermatology (co­rrespondence), 1:2, 151, August 1979.
     
    Stone SP, Goodwin RM, Evans DJ.Survival of Sarcoptes scabiei. J Am Acad Dermatol. 1980 Aug;3(2):208-9.
     
    Stone, SP:"Management of the Itchy, Scaly Scalp" in Current Concepts in Skin Disorders, 2:2, 9 - 11, Summer 1981.
     
    Wortsman J., Dietrich J., Traycoff R. B., Stone S. P.:Preradial Myxedema in Thyroid Dis­ease.Arch Derm., 117,10: 635-638, October 1981.
     
    Stone SP. Topical application of bichloroacetic acid J Dermatol Surg Oncol 1992Mar;18(3):253(Letter – Comment)
     
    Stone, SP:"Pruritus Ani and Vulvae" in Conn, H:Conn's Current Therapy 1994,W. B. Saunders (Philadelphia).
     
    Stone, SP: “Unusual, Innovative, and Long-Forgotten Remedies” in Dermatological Clinics, Theirs,BH: ed. 18:2. 323-338, April 2000.
     
    Malafa, MP, McKesey, P., Stone, SP et al: Sentinel Node Biopsy for Staging ofAggressive Digital Papillary Adenocarcinoma.  Dermatologic Surgery, 6:6 580-583, June 2000.
     
    Stone SP: Babies, Bath Water, and Accutane, Clinics in Dermatology,19:1 91-92, Jan-Feb, 2001.
     
    Stein S, Stone SP, Paller AS:Ongoing Blistering in a Boy with Congenital Erosive and Vesicular Dermatosis Healing with Reticulated Supple Scarring, J Am Acad Dermatol; 45:6 (Pt 1): 946-8 Dec2001.
     
    Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA: Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trialsHealth and Quality of Life Outcomes 2003, 1:53 (08 Oct 2003).
     
    Stone SP, Langley R (eds.): Biologic Bulletin, Recent Developments in Targeted T-Cell Therapy for Psoriasis, CD-ROM, Dannemiller Memorial Educational Foundation and Helix Medical Communications, Dec 2003.
     
    Papp KA, Camisa C, Stone SP, Caro I, Wang X, Compton P, Walicke PA, Gottlieb AB. Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data: Part II. J Cutan Med Surg. 2006 May 25; [Epub ahead of print]
     
    Stone SP, Buescher LS: Life-threatening Paraneoplastic Cutaneous Syndromes Clin Dermatol.;23(3):301-6. May-Jun 2005.
     
     
    DeWitt CA Bishop AB, Buescher LS, Stone SP:Hyperimmunoglobulin E syndrome: two cases and a review of the literature.Journal of the American Academy of Dermatology; 54(5):855-65, May 2006.
     
    CA, Neely MJ, Stone SP, Goldfarb JN: Painful plaques and cicatricial alopecia in a young woman.  Archives of Dermatology submitted
     
    CA, Siroy AE, Semans B, Stone SP:  Acneiform eruptions induced by epidermal growth factor receptor targeted chemotherapy.  J Am Acad Dermatol.  2006 Dec 11; [Epub ahead of print]  56(3):500-5 2007 Mar.
     
    Wolf R, Davidovici B, Stone SP Tuzun Y: In pursuit of defining clinical relevance of positive patch tests results.  Clin Dermatol. 2007 Sep-Oct;25(5):493-4.
     
    Reid E, Baker B, Stees M, Stone SP: Buschke-Ollendorff syndrome: A 32-month old boy with elastomas and craniosynostosis.  Pediatric Dermatology, 25(3):349-351, May/June 2008.
     
    Wolf R, Wolf D, Stone SP, Davidovici B:  Challenging the classification of clinical relevance of positive patch tests results in allergic contact dermatitis: a report on an infant.  Int J Dermatol. 2008 Nov;47(11):1193-4.
         
    BOOK  CHAPTERS

     Stone  SP: “Scabies and pediculosis” in Norman, RA, ed. Geriatric Dermatology,      Parthenon Publishing Group, 2001.

    Stone  SP: “Scabies and pediculosis”  Fitzpatrick's Dermatology in General Medicine 6th ed. 2004.

    CA, Buescher LS, Stone SP “Chapter 154:  Cutaneous Manifestations of Internal Malignant Disease: Cutaneous Paraneoplastic Syndromes” Fitzpatrick's Dermatology in General Medicine 7h ed. 2007.
     
    Stone SP, Goldfarb JN, Bacelieri RE“Chapter 208: Scabies, Pediculosis and other Mites” Fitzpatrick's Dermatology in General Medicine 7h ed. 2007
                                                                   
    REVIEWER

    Archives of Dermatology

    Journal of the American Academy of Dermatology

    Pediatric Dermatology                                                           

    Journal of Burns

    Clinical and Experimental Dermatology

    EDITORIAL

    Dialogues in Dermatology

    • Associate Editor                    1976 - 1983
    • Editor-in-Chief                      1983 – 2001
    • Consulting Editor                   2001 – 2003
    • Immediate Past Editor           2001-- 2009
    Clinics in Dermatology
    • Editorial Board       2000 –
    • Comment and Controversy Section Editor 2001                                        
     Derm Coding Consult  (American Academy of Dermatology)
    • Editorial Advisory Board        2002 - 2006   
    National Psoriasis Foundation
    • Editorial Review Committee   2003
    Cutis
    • Editorial Board 2008         

    PHARMACEUTICAL STUDIES:

    1987     CLP-503  A comparison of Temovate (clobetisol propionate) cream 0.5% and Topicort (desoximetasone) cream 0.25% in the treatment of hand and foot eczema.

    1988     FLT-335  A Multi-Center Double-Blind Active and Placebo Controlled Parallel Study of the Efficacy and Safety of .005% and .05% Fluticasone Propionate Cream in the treatment of Moderate to Severe Psoriasis (87-100).

    1997     AI459-011  A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Lobucavir in Patients with Recurrent Genital Herpes.

    1997     AI459-012  A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Lobucavir in Patients with Recurrent Herpes Labialis.

    1998     PDC501-006  A Multi-Center Double-Blind Study to Evaluate the Safety and Efficacy of Butenafine HCL/Betamethasone Dipropionate Cream in the Treatment of Tinea Pedis.

    1999     HS2A/B30009   A Randomized, Double Blind, Placebo Controlled Evaluation of Valacyclovir for the Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples.

    2000     ACD2059g  A Phase III, Randomized, Double Blind, Placebo Controlled Multicenter, Multidose Study to Evaluate the Efficacy and Safety of Subcutaneously Administered Anti-CD11a in Adults with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy

    2001     1393IMIQ  A Vehicle Controlled, Double Blind Study To Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Superficial Basal Cell Carcinoma

    2002     1423-RESI  A Phase III, Vehicle Controlled Study of Topical Resiquimod (R-848) 0.01% Gel Applied 2 Times per Week for 2 Weeks for Each Recurrence of Anogenital Herpes over 12 Months  (Study suspended/terminated early)

    2002   016.0039  A Multicenter Dose Ranging Study of the Safety and Efficacy of Enbrel in Psoriasis

    2002   ACD2600  A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0mg/kg Subcutaneously Administered Efalizumab in Adults with Moderate to Severe Plaque Psoriasis

    2002   BMV.C.302  A Multicenter, Randomized, Double Blind, Vehicle Controlled Study of the Safety and Efficacy of Luxiq® (betamethasone valerate) Foam, 0.12% in the Treatment of Moderate to Severe Atopic Dermatitis (Study on hold)

    2002   49653/331  A Randomized, Double Blind, Placebo controlled, Parallel-Group Study to Assess the Safety and Efficacy of Rosiglitazone Maleate versus Placebo in the Treatment and Maintenance of Effect in Chronic Plaque Psoriasis (co-investigator)

    2003   ACD2601g  An Open-Label, Multicenter Study to Evaluate the Safety of1.0mg/kg Subcutaneously Administered Efalizumab in Adults with Moderate to Severe Plaque Psoriasis Who Previously Enrolled in Study ACD2600g.

    2003   20030115  An Open-Label, Long-Term Extension Study to Assess the Safety of Etanercept in the Treatment of Psoriasis in Adults

    2004   20030190  A Multicenter, Open-Label, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in the Treatment of Subjects with Psoriasis.

    2004 190168-066P  A Multi-Center, Investigator-Masked Randomized Safety and Efficacy Study of 12-Weeks Treatment with Tazarotene 4.5mg Capsules Administered    Orally Once Daily vs. Efalizumab 1mg/kg Administered Subcutaneously Once Weekly vs. Tazarotene 4.5mg Capsules Administered Orally Once Daily Plus Efalizumab 1mg/kg Administered Subcutaneously Once Weekly Followed by a 12-Week Post-Treatment Follow-Up Period in Patients with Moderate to Severe Plaque Psoriasis.

    2004  BAP0008  Efficacy and Safety of BAL4079 in the Treatment of Severe Chronic Hand Dermatitis Refractory to Topical Therapy.  (Study terminated before opening).

    2004  5326-04  A Phase 2 Study of STA-5326 As Monotherapy In Patients with Chronic Moderate to Severe Plaque Psoriasis.

    2004  M03-656  A Phase 3, Multicenter Study of the Efficacy and Safety of Long-term Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis.

    2004  HS2100275  An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valaciclovir 1g Once Daily vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Infected Immunocompetent Subjects. (GlaxoSmithKline)

    2004-2005  An Open-label, Long-term Extension Study to Assess the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects. (Amgen)

    2004  20030190  A Multicenter, Open-Label, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in the Treatment of Subjects with Psoriasis. (Amgen)

    2004  190168-066P  Allergan study titled:  “A Multicenter, Investigator-Masked, Randomized Safety and Efficacy Study of 12 Weeks Treatment with Tazarotene 4.5 mg Capsules Administered Orally Once Daily vs. Efalizumab  1 mg/kg Administered Subcutaneously Once Weekly vs. Tazarotene 4.5 mg Administered Once Daily Plus Efalizumab 1 mg/kg Administered Subcutaneously Once Weekly followed by a 12 Week Post Treatment Follow up Period in Patients with Moderate to Severe Plaque Psoriasis”.

    2004 BAP00088  Basilea study titled:  “Efficacy and Safety of BAL4079 in the Treatment of Severe Chronic Hand Dermatitis Refractory to Topical Therapy”.

    2004 CSF0327C-2301 Novartis study titled:  “A Randomized, Investigator Blinded, Active-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of 6-week Treatment with Terbinafine New Pediatric Formulation Versus 6-week Treatment with Griseofulvin Pediatric Suspension in Children with Tinea Capitis”. 

    2004-2005  GlaxoSmithKline study titled:  “A Randomized, Double-Blind, Placebo-Controlled, Multicenter 60-Day Study Comparing the Efficacy of Valtrex 1 Gram Once Daily vs. Placebo Once Daily in Reducing Viral Shedding in Immunocompetent Subjects with Recurrent Genital Herpes”.

    2005  MO3-656  Abbott study titled:  “A Phase 3, Multicenter Study of the Efficacy and Safety of Long-Term Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis.”

    2005  ACD3101g Genentech study titled:  “Raptiva® Epidemiologic Study of Psoriasis Outcomes and Safety Events (RESPONSE) in Patients with Chronic Moderate to Severe Plaque Psoriasis”.

    2005  CPE.C.301  Connetics study titled:  “A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of Ethanol-Free Clobetasol Propionate Foam, 0.05% in the Treatment of Moderate to Severe Atopic Dermatitis.”

    2006   Amgen study titled: “Observational Post-Marketing Safety Surveillance Registry of Enbrel® for the Treatment of Psoriasis” Protocol 20040210.

    2006   Fujisawa study titled:  “APPLES:  A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis” Protocol FHI 03-0-161/FG-506-06-37. 

    2006  Novartis study titled:  “A 52-Week Open-Label Intermittent Treatment to Evaluate the Long-Term Safety of pimecrolimus cream 1% in seborrheic dermatitis”          Protocol CASM981N2301.

    Awards

    Canadian Dermatology Association – Honorary Membership, June 27, 2006

    “Medical Miracle Maker” Award for Research Involvement, Medical District Expo: Illinois Medical District at Springfield, June 2016

    American Academy of Dermatology, Presidential Citation, March 2006 – for service as chair of Ethics at the Solutions Summit

    American Dermatologic Association, elected 1999

    Best Doctors in America, 1998-Present

    Midwest Region, 1997-1998

    Multiple Sclerosis Society, "Class of 96" honoree, 1996

    Boneh B'rith Sholom Award, for sustained volunteer effort (with Lisa Stone) - May 1995.

    Springfield Jewish Federation Community Service Award (with Lisa Stone) February 12, 1991.

    Dickens Fellowship in Biology, Tufts University, 1962-1963

    Bachelor of Arts degree, cum laude, Tufts University, 1963

    Phi Beta Kappa, 1963.